Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13484494 | 0.85 | RAB9A (0.39) | PKMSMN1; SMN2CYP3A4MEN1KMT2A | |
| SCHEMBL577650 | 0.77 | MAPT (0.45) | SMN1; SMN2CYP3A4KMT2ARAB9ANPC1 | |
| SCHEMBL577651 | 0.75 | MAPT (0.44) | CYP3A4MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL8928677 | 0.73 | KMT2A (0.39) | CYP3A4MEN1KMT2ANPC1HPGD | |
| SCHEMBL17203079 | 0.72 | GSK3B (0.52) | SMN1; SMN2CYP3A4MEN1KMT2ARAB9A | |
| SCHEMBL29997056 | 0.69 | OPRD1 (0.39) | SMN1; SMN2CYP3A4KMT2ARAB9ANPC1 | |
| SCHEMBL3259245 | 0.69 | HDAC1 (0.51) | — | |
| SCHEMBL19511280 | 0.68 | ALDH1A1 (0.44) | SMN1; SMN2CYP3A4RAB9ANPC1HPGD | |
| SCHEMBL1561317 | 0.67 | OPRD1 (0.43) | SMN1; SMN2CYP3A4RAB9ANPC1HPGD | |
| SCHEMBL12124284 | 0.67 | KMT2A (0.61) | PKMSMN1; SMN2MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
| WO-2007014249-A2 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | JOHNS HOPKINS UNIVERSITY (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | CYP3A7, DHCR7, CYP2A7 | PKM 4510/4885SMN1; SMN2 3730/4885CYP3A4 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.